/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen Inc. (AMGN) is a California-based biopharmaceutical company focused on developing and delivering human therapeutics, especially in oncology, inflammation, bone health, and rare diseases. With a market cap of $159.7 billion, it’s known for blockbuster drugs like Prolia, Enbrel, and Repatha.
The company is expected to release its fiscal Q2 2025 earnings results after the market closes on Tuesday, Aug. 5. Ahead of this event, analysts expect AMGN to report a profit of $5.21 per share, up 4.8% from $4.97 per share in the prior year's quarter. It has consistently surpassed Wall Street's bottom-line estimates in the past four quarters.